These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 24450570)

  • 1. Use of alfacalcidol in osteoporotic patients with low muscle mass might increase muscle mass: an investigation using a patient database.
    Ito S; Harada A; Kasai T; Sakai Y; Takemura M; Matsui Y; Hida T; Ishiguro N
    Geriatr Gerontol Int; 2014 Feb; 14 Suppl 1():122-8. PubMed ID: 24450570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfacalcidol versus plain vitamin D in the treatment of glucocorticoid/inflammation-induced osteoporosis.
    Ringe JD; Faber H; Fahramand P; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():33-40. PubMed ID: 16142849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures.
    Schacht E; Richy F; Reginster JY
    J Musculoskelet Neuronal Interact; 2005; 5(3):273-84. PubMed ID: 16172518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol].
    Galeşanu C; Ciubotariu C; Melnic G; Galeşanu MR
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(4):833-41. PubMed ID: 17438884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia and sarcopenic obesity among men aged 80 years and older in Beijing: prevalence and its association with functional performance.
    Meng P; Hu YX; Fan L; Zhang Y; Zhang MX; Sun J; Liu Y; Li M; Yang Y; Wang LH; Zhang Y; Gao W; Han XQ; Chen LK
    Geriatr Gerontol Int; 2014 Feb; 14 Suppl 1():29-35. PubMed ID: 24450558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potency of a combined alfacalcidol-alendronate therapy to reduce the risk of falls and fractures in elderly patients with glucocorticoid-induced osteoporosis.
    Ringe JD; Schacht E; Dukas L; Mazor Z
    Arzneimittelforschung; 2011; 61(2):104-11. PubMed ID: 21428245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low free testosterone is associated with loss of appendicular muscle mass in Japanese community-dwelling women.
    Yuki A; Ando F; Otsuka R; Shimokata H
    Geriatr Gerontol Int; 2015 Mar; 15(3):326-33. PubMed ID: 24629182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relationship between Skeletal Muscle Mass and Bone Mass at Different Sites in Older Adults.
    Chen L; Wu J; Ren W; Li X; Luo M; Hu Y
    Ann Nutr Metab; 2023; 79(2):256-262. PubMed ID: 36521447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age-related skeletal muscle mass loss and physical performance in Taiwan: implications to diagnostic strategy of sarcopenia in Asia.
    Liu LK; Lee WJ; Liu CL; Chen LY; Lin MH; Peng LN; Chen LK
    Geriatr Gerontol Int; 2013 Oct; 13(4):964-71. PubMed ID: 23452090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
    Iwasaki T; Nonoda Y; Ishii M
    Curr Med Res Opin; 2012 May; 28(5):737-47. PubMed ID: 22126423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The D-hormone analog alfacalcidol: the pioneer beyond the horizon of osteoporosis treatment.
    Orimo H; Schacht E
    J Rheumatol Suppl; 2005 Sep; 76():4-10. PubMed ID: 16142845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alfacalcidol improves muscle power, muscle function and balance in elderly patients with reduced bone mass.
    Schacht E; Ringe JD
    Rheumatol Int; 2012 Jan; 32(1):207-15. PubMed ID: 20827552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age-related changes in skeletal muscle mass among community-dwelling Japanese: a 12-year longitudinal study.
    Shimokata H; Ando F; Yuki A; Otsuka R
    Geriatr Gerontol Int; 2014 Feb; 14 Suppl 1():85-92. PubMed ID: 24450565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alfacalcidol reduces accelerated bone turnover in elderly women with osteoporosis.
    Shiraki M; Fukuchi M; Kiriyama T; Okamoto S; Ueno T; Sakamoto H; Nagai T
    J Bone Miner Metab; 2004; 22(4):352-9. PubMed ID: 15221494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a six-month therapy with alfacalcidol on muscle power and balance and the number of fallers and falls.
    Dukas L; Schacht E; Runge M; Ringe JD
    Arzneimittelforschung; 2010; 60(8):519-25. PubMed ID: 20863009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alfacalcidol versus plain vitamin D in inflammation induced bone loss.
    Scharla SH; Schacht E; Lempert UG
    J Rheumatol Suppl; 2005 Sep; 76():26-32. PubMed ID: 16142848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alfacalcidol in men with osteoporosis: a prospective, observational, 2-year trial on 214 patients.
    Ringe JD; Farahmand P; Schacht E
    Rheumatol Int; 2013 Mar; 33(3):637-43. PubMed ID: 22527138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type 2 diabetes is associated with low muscle mass in older adults.
    Kim KS; Park KS; Kim MJ; Kim SK; Cho YW; Park SW
    Geriatr Gerontol Int; 2014 Feb; 14 Suppl 1():115-21. PubMed ID: 24450569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk reduction of falls and fractures, reduction of back pain and safety in elderly high risk patients receiving combined therapy with alfacalcidol and alendronate: a prospective study.
    Schacht E; Ringe JD
    Arzneimittelforschung; 2011; 61(1):40-54. PubMed ID: 21355445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.